ELITE’s Post

What did the last pharmaceutical market overview for Finland, Sweden, and Norway look like for the year 2023? IQVIA’s market data for December shows among other things that the top health company in Finland was Orion Pharma with sales of 27M EUR for the month and 292M EUR for the year. The top product was Eliquis by Brist-Myers Squibb. In the Swedish market, the monthly market growth was 6.3%. The top health company was Janssen-Cilag with sales of 267M SEK for the month and 3.217M SEK for the year. The Norwegian market showed high monthly growth with more than 17% partly driven by the top selling product Wegovy FlexTouch by Novo Nordisk with sales of 108M NOK for the month and 691M NOK for the year. #iqvia #iqvianordics

Pharmaceutical Group of the European Union (PGEU) President Aris Prins and FIP President Paul Sinclair met during the International Pharmaceutical Federation (FIP) Congress in Cape Town. The discussion underscored the shared commitment to advancing #pharmacy practice globally. By reaffirming the longstanding and fruitful cooperation between our organizations, we are better equipped to address common priorities, enhance the role of #pharmacists, and ultimately improve #patient care. Exciting times ahead as we continue to work hand in hand for the future of pharmacy! #FIPCongress2024

Association of the British Pharmaceutical Industry This report highlights the impact of NHS-industry partnerships on patient outcomes. Research shows that hospitals collaborating with industry are significantly more aligned with NICE recommendations for prescribing medicines, leading to better patient care. #NHS #healthcare #partnerships #research #abpi

In case anyone needs to be reminded that #drugpricing is complex, here is the Producer Price Index (#PPI) for Pharmaceutical Preparation Manufacturing (price received by pharmaceutical manufacturers) and Pharmacies and Drug Retailers (price received by retailers) along with the Consumer Price Index (#CPI) for Prescription Drugs (price paid by consumers out of pocket or by third party payers including insurance or government). (Data accessed 3/21/2024). What do you think? Bentley University Center for Health and Business Center for Integration of Science and Industry at Bentley University @Bentley University

Kimberly Westrich (Chief Strategy Officer, National Pharmaceutical Council) shares her highlights in US healthcare value and access from March and April 2024. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #hta #healthtechnologyassessment #healthdata #ISPORAnnual

Buy Direct with NuCare Pharmaceuticals! 🚀 For over 20 years, NuCare Pharmaceuticals has been a trusted name in the industry, and we’re excited to announce a game-changing move in the GLP-1 market! As the unprecedented GLP-1 patient demand continues with semaglutide and tirzepatide leading the charge, we're committed to offering you top-quality products at unbeatable prices. 💊✨ We source exclusively from FDA-registered manufacturers and rigorously third-party test all our products to ensure the highest standards. Unfortunately, we’ve noticed that some companies are buying our products and reselling them at inflated prices. 😠 At NuCare, we believe in integrity and value over profits. That’s why we’re cutting our prices to beat the middleman and ensure you get the best deal possible. 💰🔍 If you're a 503a or 503b pharmacy not currently buying directly from us, we urge you to make the switch. We guarantee a minimum savings of $100 per gram compared to what you’re currently paying. Let's build a long-lasting partnership where quality and savings go hand in hand. 🤝💼 Discover the NuCare difference today and experience the value we bring to the table. Visit us at https://lnkd.in/dwq2SSfw for more details and to make the switch. #Pharmaceuticals #GLP1 #Semaglutide #Tirzepatide #Integrity #Value #NuCarePharmaceuticals #API #Pharmacy

Here's my latest guest column with The Evidence Base® capturing value highlights from March and April.

NEW on our Health Research and Innovation Blog: More than just medicines - Canada’s innovative pharmaceutical industry is contributing to the country’s overall health From groundbreaking research to cutting-edge treatments, learn how these advancements are shaping a healthier future for all Canadians. Read the full article from Innovative Medicines Canada - Médicaments novateurs Canada at https://lnkd.in/gcuf6Szv

Governments should ensure that access to medicines and medical devices is always accompanied by access to pharmacists and pharmaceutical expertise, FIP says in a statement of policy, published today. With this statement, FIP makes a number of recommendations for how different groups of stakeholders can improve access to safe and quality essential medicines. In particular, the policy highlights a significant difference in medicines access between low- and high-income countries, with disparities in the structure of healthcare systems and the numbers and roles of pharmacists and pharmacies being among the contributing causes. Read the statement here https://lnkd.in/g-jiWPJd credit International Pharmaceutical Federation (FIP)

I'm watching a mom go back and forth with a pharmacist for prescription drugs at a pharmacy and none of the options (including generics) seem affordable. Pharmaceutical drugs are a critical pillar of healthcare, demanding a much-needed conversation about value-based pricing. The current state of pharmaceutical pricing is unsustainable. Many #PBM cost structures are simply ridiculous without a clear correlation to patient outcomes. The emergence of cost-plus pharmacies is a testament to the market's need for change. It's time for a broader coalition involving payers, providers, and drug manufacturers to come together and find solutions. We need to rethink our approach and implement a more sustainable model that prioritizes value over cost. #valuebasedpharma